JP2011200233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011200233A5 JP2011200233A5 JP2011095100A JP2011095100A JP2011200233A5 JP 2011200233 A5 JP2011200233 A5 JP 2011200233A5 JP 2011095100 A JP2011095100 A JP 2011095100A JP 2011095100 A JP2011095100 A JP 2011095100A JP 2011200233 A5 JP2011200233 A5 JP 2011200233A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cytotoxic agent
- protein
- seq
- agent conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 31
- 229940127089 cytotoxic agent Drugs 0.000 claims description 28
- 239000002254 cytotoxic agent Substances 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 19
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 12
- 201000000849 skin cancer Diseases 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
- 108010066676 Abrin Proteins 0.000 claims description 4
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 claims description 2
- 101001123514 Arabidopsis thaliana Pectinesterase 40 Proteins 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229930183665 actinomycin Natural products 0.000 claims description 2
- 108010001818 alpha-sarcin Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- 229960001338 colchicine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010028531 enomycin Proteins 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 108010010621 modeccin Proteins 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 108010076042 phenomycin Proteins 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 description 31
- 125000003729 nucleotide group Chemical group 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 108091033319 polynucleotide Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44663303P | 2003-02-10 | 2003-02-10 | |
| US60/446,633 | 2003-02-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503486A Division JP2007524361A (ja) | 2003-02-10 | 2004-02-10 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246948A Division JP2015057068A (ja) | 2003-02-10 | 2014-12-05 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011200233A JP2011200233A (ja) | 2011-10-13 |
| JP2011200233A5 true JP2011200233A5 (cg-RX-API-DMAC7.html) | 2012-09-06 |
Family
ID=32869540
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503486A Pending JP2007524361A (ja) | 2003-02-10 | 2004-02-10 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
| JP2011095100A Pending JP2011200233A (ja) | 2003-02-10 | 2011-04-21 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
| JP2014246948A Pending JP2015057068A (ja) | 2003-02-10 | 2014-12-05 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503486A Pending JP2007524361A (ja) | 2003-02-10 | 2004-02-10 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246948A Pending JP2015057068A (ja) | 2003-02-10 | 2014-12-05 | 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP2343315A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2007524361A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2004210975B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2515699C (cg-RX-API-DMAC7.html) |
| IL (1) | IL170080A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004072263A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501741D0 (en) * | 2005-01-27 | 2005-03-02 | Binding Site The Ltd | Antibody |
| EP1840133A1 (en) * | 2006-03-29 | 2007-10-03 | Global Biotech Development Corp. Ltd. | New immunomodulating oligopeptides |
| KR20150038522A (ko) * | 2006-03-31 | 2015-04-08 | 알닐람 파마슈티칼스 인코포레이티드 | Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산 |
| JP2013179911A (ja) * | 2012-03-02 | 2013-09-12 | Dainippon Printing Co Ltd | 電極付き細胞試験具の接続装置、及びそれを用いた細胞試験装置 |
| KR102274722B1 (ko) * | 2012-08-23 | 2021-07-09 | 어젠시스 인코포레이티드 | 158p1d7 단백질에 결합하는 항체 |
| US11471538B2 (en) * | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| JPWO2023105976A1 (cg-RX-API-DMAC7.html) * | 2021-12-08 | 2023-06-15 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DK0462145T3 (da) | 1989-03-07 | 1994-08-08 | Genentech Inc | Covalente konjugater mellem lipid og oligonucleotid |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| JP3056782B2 (ja) | 1989-11-03 | 2000-06-26 | ヴァンダービルト ユニバーシティ | 標的器官内での遺伝子の発現用医薬組成物 |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| EP1013666B1 (en) | 1990-06-27 | 2006-05-10 | Princeton University | Protein complex p53/p90 |
| SE9002480D0 (sv) | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| NZ255683A (en) | 1992-08-07 | 1996-08-27 | Cytel Corp | Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif |
| WO1994020127A1 (en) | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
| EP0702716A4 (en) | 1993-05-17 | 1999-05-26 | Univ California | RIBOZYMIC GENE THERAPY FOR HIV INFECTION AND AIDS |
| US5837501A (en) | 1993-07-09 | 1998-11-17 | Akzo Nobel N.V. | Nucleic acid quantitation by co-amplification of target with multiple internal controls |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| ATE415173T1 (de) | 1993-09-14 | 2008-12-15 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| EP1405911A1 (en) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1996032503A1 (en) | 1995-04-11 | 1996-10-17 | The General Hospital Corporation | Reverse two-hybrid systems |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP0914142B9 (en) | 1996-03-11 | 2012-01-04 | Epimmune Inc. | Peptides with increased binding affinity for at least three hla-a3-like molecules |
| JP2000508923A (ja) | 1996-04-26 | 2000-07-18 | マサチューセッツ・インスティテュート・オブ・テクノロジー | ３―ハイブリッド・スクリーニング・アッセイ |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6365797B1 (en) | 1997-10-15 | 2002-04-02 | The Regents Of The University Of California | Mice models of human prostate cancer progression |
| ES2290964T3 (es) | 1996-10-15 | 2008-02-16 | The Regents Of The University Of California | Modelos animales de la evolucion del cancer de prostata humano. |
| US5846722A (en) | 1996-10-16 | 1998-12-08 | Terrapin Technologies, Inc. | System to detect small molecule/peptide interaction |
| US5840501A (en) | 1996-10-25 | 1998-11-24 | Bayer Corporation | Determination of cPSA |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| AU2001257265A1 (en) * | 2000-04-27 | 2001-11-07 | Smithkline Beecham Corporation | Novel compounds |
| WO2002016598A2 (en) * | 2000-08-22 | 2002-02-28 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers |
| CA2419979A1 (en) * | 2000-09-08 | 2002-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
| WO2002026826A2 (en) * | 2000-09-27 | 2002-04-04 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2002059377A2 (en) * | 2001-01-24 | 2002-08-01 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| WO2003102155A2 (en) * | 2002-06-03 | 2003-12-11 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2013037693A2 (de) | 2011-09-15 | 2013-03-21 | Convergent Information Technologies Gmbh | System und verfahren zur automatisierten erstellung von roboterprogrammen |
-
2004
- 2004-02-10 CA CA2515699A patent/CA2515699C/en not_active Expired - Lifetime
- 2004-02-10 WO PCT/US2004/003984 patent/WO2004072263A2/en not_active Ceased
- 2004-02-10 EP EP10075689A patent/EP2343315A3/en not_active Withdrawn
- 2004-02-10 CA CA2860151A patent/CA2860151A1/en not_active Abandoned
- 2004-02-10 EP EP04709923A patent/EP1594892A2/en not_active Withdrawn
- 2004-02-10 AU AU2004210975A patent/AU2004210975B2/en not_active Expired
- 2004-02-10 JP JP2006503486A patent/JP2007524361A/ja active Pending
-
2005
- 2005-08-04 IL IL170080A patent/IL170080A/en active IP Right Grant
-
2008
- 2008-07-10 AU AU2008203053A patent/AU2008203053B2/en not_active Expired
-
2010
- 2010-04-22 AU AU2010201615A patent/AU2010201615B2/en not_active Expired
-
2011
- 2011-04-21 JP JP2011095100A patent/JP2011200233A/ja active Pending
-
2014
- 2014-12-05 JP JP2014246948A patent/JP2015057068A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162950B2 (en) | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis | |
| JP2018115162A (ja) | 新規モジュレータ及びその使用法 | |
| JP2011200233A5 (cg-RX-API-DMAC7.html) | ||
| CN101925612A (zh) | 针对癌相关的nfkbib变体的表位的抗体及其用途 | |
| RU2015108348A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| CN111278847B (zh) | 分子导向系统肽及其用途 | |
| US20240317890A1 (en) | Her2 single domain antibodies variants and cars thereof | |
| KR20140103122A (ko) | 신경교종을 치료하기 위한 조성물 및 방법 | |
| CA2522994A1 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
| CN119421897A (zh) | 抗ror1抗体 | |
| US20220242964A1 (en) | Compositions and methods for regulating erythropoiesis | |
| JP5843170B2 (ja) | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 | |
| TW201111510A (en) | Recombinant nucleotide sequence, cell or vector containing the recombinant nucleotide sequence, recombinant single chain anti-polyethylene glycol membrane antibody encoded thereof and method for using the cell containing the recombinant nucleotide sequen | |
| US20240307531A1 (en) | Compositions and methods of treating sarcoma lung metastasis | |
| CN103800919A (zh) | Tuft1在制备肝癌诊断和治疗制剂中的应用 | |
| KR100958943B1 (ko) | 쥐알파12/쥐알파13 단백질 기능의 하향 조절제를 포함하는전환성장인자베타 1 (티쥐에프 베타 1) 관련 질병의 예방또는 치료용 약학 조성물 | |
| US20150212086A1 (en) | Diagnosis and Treatment of Brain Tumor | |
| CN107614524B (zh) | 治疗 | |
| CA2420990A1 (en) | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer | |
| JP2005508157A5 (cg-RX-API-DMAC7.html) | ||
| TW202535920A (zh) | 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用 | |
| JP2013147464A (ja) | 医薬組成物 |